Durvalumab consolidation therapy in patients with stage III non-small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis

This publication has 37 references indexed in Scilit:

• The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC
  Annals of Oncology, 2017
• Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds
  Health Policy and Planning, 2016
• Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis
  Critical Reviews in Oncology/Hematology, 2016
• Health state utilities in non–small cell lung cancer: An international study
  Asia-Pacific Journal of Clinical Oncology, 2016
• The Role of PD-L1 Expression as a Predictive Biomarker in Advanced Non-Small-Cell Lung Cancer: A Network Meta-Analysis
  Immunotherapy, 2016
• Comorbidity and Survival in Lung Cancer Patients
  Cancer Epidemiology, Biomarkers & Prevention, 2015
• Reference Intervals for Total Bilirubin, ALT, AST and Creatinine in Healthy Chinese Elderly
  Medical Science Monitor, 2014
• Economic Evaluation of First-Line Treatments for Metastatic Renal Cell Carcinoma: A Cost-Effectiveness Analysis in A Health Resource–Limited Setting
  PLOS ONE, 2012
• Improved curve fits to summary survival data: application to economic evaluation of health technologies
  BMC Medical Research Methodology, 2011
• Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey
  Journal of Thoracic Oncology, 2010